Liquid Biopsy Global Market - Forecast to 2024

Published by IQ4I on 19th March 2018 | Ref: 1005277 | This Report Is In Stock

$4950 | Single User
$6750 | Site License
$9000 | Enterprise License
$4950 | Single User
$6750 | Site License
$9000 | Enterprise License

Introduction

Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.

According to IQ4I analysis, the liquid biopsy global market is projected to grow at double digit CAGR to reach ,730.4 million by 2024.

The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.

The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.

The oncology testing market is segmented based on type of cancer into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is segmented based on cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates with share in 2017, while early screening is expected to grow at strong CAGR of 22.3% from 2017 to 2024.

The liquid biopsy sample market includes into blood, urine and others where blood dominates the market revenue of ,881.9 million in 2017 and is expected to maintain the position with strong CAGR growth during forecasting period.

The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017 and are expected to show strong CAGR from 2017 to 2024.

The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW where North America dominates the market in 2017 followed by Europe. Asia-Pacific market is expected to show highest growth rate during forecasting period.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World (RoW)

Table of Contents

1 EXECUTIVE SUMMARY 27

2 INTRODUCTION 36

2.1 KEY TAKE AWAYS 36

2.2 REPORT DESCRIPTION 37

2.3 MARKETS COVERED 39

2.4 STAKEHOLDERS 41

2.5 RESEARCH METHODOLOGY 41

3 MARKET ANALYSIS 50

3.1 INTRODUCTION 50

3.2 MARKET SEGMENTATION 51

3.3 FACTORS INFLUENCING MARKET 53

biopsy procedures 55

3.4 REGULATORY AFFAIRS 63

3.5 PORTER’S FIVE FORCE ANALYSIS 66

3.6 PATENT TRENDS 69

3.7 MARKET SHARE ANALYSIS 71

3.8 REIMBURSEMENT SCENARIO 77

3.9 CLINICAL TRIALS 80

3.10 TECHNOLOGICAL ADVANCEMENTS 97

3.11 UPCOMING TESTS 99

3.12 RESEARCH USE ONLY CELL-FREE DNA TESTS 102

3.13 FUNDING SCENARIO 104

3.14 LIQUID BIOPSY COMPANY COMPARISON BY APPLICATIONS 114

4 MARKET SIZING 126

4.1 U.S.LIQUID BIOPSY MARKET SIZING INFORMATION 126

5 LIQUID BIOPSY GLOBAL MARKET, BY BIOMARKER 134

5.1 INTRODUCTION 134

5.2 CIRCULATING TUMOUR CELLS (CTC) 137

5.3 CELL-FREE DNA (CFDNA) 141

5.4 EXOSOMES & OTHERS 144

6 LIQUID BIOPSY GLOBAL MARKET, BY APPLICATION 149

6.1 INTRODUCTION 149

6.2 ONCOLOGY TESTING 152

6.3 PRENATAL TESTING 203

6.4 TRANSPLANTATION 206

7 LIQUID BIOPSY GLOBAL MARKET, BY SAMPLE 209

7.1 INTRODUCTION 209

7.2 BLOOD 211

7.3 URINE AND OTHERS 215

8 LIQUID BIOPSY GLOBAL MARKET, BY END-USERS 219

8.1 INTRODUCTION 219

8.2 HOSPITALS 222

8.3 ACADEMIC & RESEARCH INSTITUTES 225

9 REGIONAL ANALYSIS 229

9.1 INTRODUCTION 229

9.2 NORTH AMERICA 232

9.3 EUROPE 254

9.4 ASIA-PACIFIC 284

9.5 REST OF THE WORLD (ROW) 314

10 COMPETITIVE LANDSCAPE 340

10.1 INTRODUCTION 340

10.2 AGREEMENTS 341

10.3 COLLABORATIONS/PARTNERSHIPS 354

10.4 NEW PRODUCT LAUNCHES 362

10.5 APPROVALS 370

10.6 ACQUSTIONS 372

10.7 OTHERS 374

11 MAJOR COMPANIES 382

11.1 BGI (BGI DIAGNOSTICS) 382

11.2 BIOCEPT, INC. 387

11.3 CAREDX, INC. 400

11.4 CYNVENIO BIOSYSTEMS, INC 408

11.5 EUROFINS SCIENTIFIC SE (LIFECODEXX) 415

11.6 EXACT SCIENCES CORPORATION 422

11.7 EXOSOME DIAGNOSTICS, INC 427

11.8 GUARDANT HEALTH, INC. 434

11.9 ILLUMINA, INC. 443

11.10 IMMUCOR 450

11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS 456

11.12 MDX HEALTH 463

11.13 MYRIAD GENETICS, INC. 472

11.14 NATERA, INC. 480

11.15 ROCHE HOLDINGS AG 488

Additional Details

Publisher

IQ4I

Publisher Information

Reference

1005277 |

Number of Pages

496

Report Format

PDF

This report is published by IQ4I

Download Free Report Summary PDF

Liquid Biopsy Global Market - Forecast to 2024 [Updated: 19-03-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.